[akita]

http://ash.confex.com/ash/2010/webpr...aper31528.html

1826 The Oral Iron Chelator Deferasirox for Treatment of Transfusional Iron Overload After Allogeneic Hematopoietic Cell Transplantation Does Not Appear to Interfere with the Calcineurin Inhibitor Cyclosporin Trough Serum Levels

---
The study deals with the safety of concomitant management of cyclosporin and Exjade after SZT.


Many patients that have undergone SZT have an transfusional iron overload that contributes to treatment-related morbidity and mortality of transplantation. Iron chelation eliminates that overload. But typically these patients have immunsuppressive medication e.g. Cyclosporin. Here the "trough serum cyclosporin level (TSCL)" has to be managed. The data of the study demonstrate, that adequate management of TSCL and iron chelation per deferasirox go together, that Exjade does not change the TSCL.

Citation: "In conclusion, our data demonstrate clearly that maintaining an adequate TSCL in transplanted patients is not complicated by the concomitant treatment with deferasirox."